|
| Press Releases |
|
 |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
|
新版國家醫保藥品目錄落地 全球首個IgA腎病對因治療藥物耐賦康(R)納入報銷 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈隨著《國家基本醫療保險、工傷保險和生育保險藥品目錄（2024年）》（「國家醫保藥品目錄」）2025年1月1日正式實施，耐賦康(R)（布地奈德腸溶膠囊，NEFECON(R)）將開始執行醫保新價格，各地IgA腎病患者將陸續享受醫保報銷。 more info >> |
|
|
新版国家医保药品目录落地 全球首个IgA肾病对因治疗药物耐赋康(R)纳入报销 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布随着《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》（"国家医保药品目录"）2025年1月1日正式实施，耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）将开始执行医保新价格，各地IgA肾病患者将陆续享受医保报销。 more info >> |
|
| Wednesday, December 18, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China. more info >> |
|
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）大灣區內地首張處方在佛山正式落地 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈伊曲莫德（VELSIPITY(R), etrasimod）通過「港澳藥械通」政策，在廣東佛山複星禪誠醫院開出粵港澳大灣區內地首張處方，標誌著伊曲莫德開始正式惠及中國大陸患者。 more info >> |
|
|
云顶新耀宣布伊曲莫德（VELSIPITY(R)）大湾区内地首张处方在佛山正式落地 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布伊曲莫德（VELSIPITY(R), etrasimod）通过“港澳药械通”政策，在广东佛山复星禅诚医院开出粤港澳大湾区内地首张处方，标志着伊曲莫德开始正式惠及中国大陆患者。 more info >> |
|
| Tuesday, December 17, 2024 |
|
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY is an effective and convenient, once-daily, oral treatment for patients with moderately to severely active UC. more info >> |
|
|
雲頂新耀宣佈中國國家藥品監督管理局正式受理伊曲莫德（VELSIPITY(R)） |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈中國國家藥品監督管理局已正式受理伊曲莫德（VELSIPITY(R)）用於治療中重度活動性潰瘍性結腸炎（UC）患者的新藥上市許可申請（NDA）。 more info >> |
|
|
云顶新耀宣布中国国家药品监督管理局正式受理伊曲莫德（VELSIPITY(R)） |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布中国国家药品监督管理局已正式受理伊曲莫德（VELSIPITY(R)）用于治疗中重度活动性溃疡性结肠炎（UC）患者的新药上市许可申请（NDA）。 more info >> |
|
| Thursday, December 12, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
珠宝双展匯聚逾82,000环球买家
Mar 9, 2025 13:51 HKT/SGT
|
|
|
珠寶雙展匯聚逾82,000環球買家
Mar 9, 2025 13:41 HKT/SGT
|
|
|
Twin jewellery shows attract over 82,000 global buyers
Mar 9, 2025 13:19 HKT/SGT
|
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 8, 2025 19:40 HKT/SGT
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 8, 2025 19:20 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 21:26: JST
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 7, 2025 20:31: JST
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 7, 2025 19:24 HKT/SGT
|
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 7, 2025 19:16 HKT/SGT
|
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 7, 2025 18:28 HKT/SGT
|
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 7, 2025 18:10 HKT/SGT
|
|
|
東信營銷科技：中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證
Mar 7, 2025 17:58 HKT/SGT
|
|
|
东信营销科技：中国AI营销龙头斩获多模态双备案 技术实力获国家级认证
Mar 7, 2025 17:20 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 7, 2025 16:24 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
